Slovenian Company Cosylab Achieves Major Milestone in Cancer Treatment Technology

Ljubljana-based Cosylab, a globally recognized Slovenian high-tech firm, has introduced PlanOne, a novel system designed for planning cancer treatment using particle therapy. This software empowers physicians and medical physicists to meticulously map out radiation treatments involving protons and other charged particles.

The company has secured approval for PlanOne from the U.S. Food and Drug Administration (FDA). This development is a major milestone for Cosylab, which has historically functioned as a development partner for medical device manufacturers and research institutions. PlanOne represents their first self-developed healthcare product intended for sale to hospitals worldwide.

Previously, Cosylab focused on creating products sold to other manufacturers, serving a limited number of clients. "Until now, we developed products that we sold to other manufacturers of these devices. There were five or ten such clients. Now we have a product that...", the article states, highlighting the shift in their business model.

The PlanOne system utilizes artificial intelligence to identify critical organs such as the heart and spinal cord. A medical professional then reviews and refines the AI's suggestions. "Artificial intelligence is a help, not a replacement for an expert," emphasizes the article, underscoring the collaborative role of technology in medical practice.

“

The program can identify the heart, spinal cord, or other organs, and the doctor then checks and corrects the result if necessary. Artificial intelligence is a help, not a replacement for an expert.